A possible new treatment for elevated Lp(a) in CVD - HORIZON
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease (CVD).
Novartis Pharma AG
Duration of Study in the UK
3 years, 7 months, 3 days
Lipoprotein (a) is recognised as an independent risk factor biomarker for Cardiovascular Disease. This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a). The study population will consist of subjects with established CVD; 7,680 males and females; age 18 to 80 years both inclusive.
North West - Greater Manchester South Research Ethics Committee
Date of REC Opinion
17 Sep 2020
Further Information Favourable Opinion